Details for Patent: 9,669,096

Which drugs does patent 9,669,096 protect, and when does it expire?

Patent 9,669,096 protects RELISTOR and is included in one NDA.

This patent has forty-five patent family members in nineteen countries.

Summary for Patent: 9,669,096

Title:	Stable pharmaceutical formulations of methylnaltrexone
Abstract:	Stable pharmaceutical compositions useful for administering methylnaltrexone are described, as are methods for making the same. Kits, including these pharmaceutical compositions, also are provided.
Inventor(s):	Sanghvi; Suketu P. (Kendall Park, NJ), Boyd; Thomas A. (Grandview, NY)
Assignee:	Progenics Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	14/039,866
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,669,096
Patent Claim Types: see list of patent claims	Composition; Formulation; Compound;

Drugs Protected by US Patent 9,669,096

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-002	Sep 27, 2010	AP	RX	Yes	Yes			Y
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-001	Apr 24, 2008		RX	Yes	Yes			Y
Salix Pharms	RELISTOR	methylnaltrexone bromide	SOLUTION;SUBCUTANEOUS	021964-003	Sep 27, 2010	AP	RX	Yes	Yes			Y

International Family Members for US Patent 9,669,096

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004229463
Australia	2010202824
Australia	2013203378
Brazil	PI0409133
Canada	2521379